Navigation Links
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Date:1/26/2009

key contributors to why physicians have quickly adopted XIENCE V, making it the market-leading drug eluting stent in the United States and in key markets around the world."

About the SPIRIT III Trial

SPIRIT III is a prospective, multi-center, randomized, single-blind, controlled clinical trial comparing XIENCE V to TAXUS in 1,002 patients (669 XIENCE V patients, 333 TAXUS patients) with either one or two de novo native coronary artery lesions. The trial was conducted across 65 academic and community-based centers in the United States between June 22, 2005, and March 15, 2006.

The primary endpoint of the SPIRIT III trial was in-segment late loss at eight months, wherein XIENCE V demonstrated superiority to TAXUS with a statistically significant 50 percent reduction in late loss (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS). In-segment late loss is a measure of vessel renarrowing. In the co-primary endpoint of TVF at nine months, XIENCE V demonstrated statistical non-inferiority compared to TAXUS with an observed 20 percent reduction in TVF (7.2 percent for XIENCE V vs. 9.0 percent for TAXUS).

Additionally, in the pre-specified secondary endpoint of MACE, XIENCE V demonstrated a 43 percent reduction at nine months (4.6 percent for XIENCE V vs. 8.1 percent for TAXUS) and a 42 percent reduction in MACE at one year (6.0 percent for XIENCE V vs. 10.3 percent for TAXUS) compared to TAXUS.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
5. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
11. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... FALLS, N.J. , May 1, 2015 CANTEL ... Andrew A. Krakauer , Chief Executive Officer, will be presenting ... at the Encore at the Wynn in Las ... Thursday, May 14, 2015 at 10:00 AM PT/1:00 PM ET. ... during the day. An audio webcast will ...
(Date:5/1/2015)... , May 1, 2015  Portal Instruments, Inc., ... delivery systems, announced today that Robert Langer, Sc. ... Ph.D., University of Auckland Distinguished Professor have joined the ... to welcome two esteemed biotechnology leaders, Professor Robert ... our team," said Dr. Patrick Anquetil , Chief ...
(Date:5/1/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world leader in ... hearts, announced today that Marta Antonucci has joined ... This new Europe -based position is ... North America , including Europe , ... , and reports directly to the Chief Executive Officer. Following ...
Breaking Medicine Technology:Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 2Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 3Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 4Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3
... 1, 2011 Milestone Scientific Inc. (OTCQB: MLSS), the ... the Company filed its 2010 year-end results for the ... Securities & Exchange Commission on Wednesday, March 30, 2011. ... teleconference Monday, April 4, 2011 beginning at 4:15 PM ...
... 2011 New data presented today at the 46th ... of the Liver (EASL) demonstrate the antiviral activity of ... both treatment-naive and -experienced patients with chronic genotype-1 (GT1) ... HCV to treat.  Results from SILEN-C1 show a sustained ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 3Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 4Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 5Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 6
(Date:5/3/2015)... 03, 2015 SpineFrontier, a Less Exposure ... FDA to produce and market their new sacroiliac joint ... used in outpatient settings and is compatible with both ... approach has been extensively researched and refined by SpineFrontier, ... use this approach in conjunction with a sacroiliac joint ...
(Date:5/2/2015)... As one of only 30 Illinois companies ... Health Achievement and Recognition Program (SHARP) certification, Essentra ... the Illinois Department of Labor to host this special ... certification by the Occupational Safety and Health Administration’s (“OSHA”) ... to meet or exceed all of the necessary regulations ...
(Date:5/2/2015)... ” was featured on NewsWatch as part of its monthly ... applications on the market for iOS, Android, and Windows. Joe ... app review and shared with viewers how this app allows ... , In this material world, almost everything is about money. ... is why those things should be prioritized above others. And ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... May 02, 2015 Kare Visits LLC. launched ... for busy caregivers. Kare Visits offers relief for caregivers ... living facilities. According to the Caregiver Action Network, ... average of 20 hours a week caring for an elderly ... cost to hire a nurse, a caregiver is now empowered ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2
... AUGUSTA, Ga. A new strategy that takes advantage of ... extra months of life with few side effects, researchers say., ... a sort of front door by pairing a substance attracted ... be given systemically, said Dr. Sharad Ghamande, Chief of the ...
... BOSTON -- Even yeast understand austerity. A finely tuned system evolved ... times come as fast as they go. The system, a molecular ... protein that turns growth on in times of plenty and shuts ... lab of Wenyi Wei, PhD, an investigator in the Department of ...
... Reporter , THURSDAY, Oct. 27 (HealthDay News) -- Two aspirin a ... half in people who are predisposed to these types of tumors, ... each also cut the risk of other tumors related to Lynch ... to research published in the Oct. 28 online edition of ...
... Reinberg HealthDay Reporter , THURSDAY, Oct. 27 (HealthDay ... part B benefits in 2012 will be less than expected ... U.S. health officials said Thursday. However, for those already ... most people with Medicare have paid a monthly premium of ...
... fourth-generation oncolytic virus designed to both kill cancer cells ... earlier versions when tested in animal models of human ... University Comprehensive Cancer Center Arthur G. James Cancer ... James) are developing the oncolytic virus as a treatment ...
... 27, 2011Bruce Beutler, MD, a co-recipient of the 2011 Nobel ... molecular mechanism that can cause the body to attack itself ... ahead of print in Journal of Interferon & Cytokine ... Inc. ( www.liebertpub.com ) and is available free at ...
Cached Medicine News:Health News:Folate receptors may serve as a front door to ovarian cancer treatment 2Health News:Unraveling the complex signaling that helps cells know when to grow, when to sit tight 2Health News:Unraveling the complex signaling that helps cells know when to grow, when to sit tight 3Health News:Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk 2Health News:Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk 3Health News:Medicare Part B Premium Increase Lower Than Expected 2Health News:New oncolytic virus shows improved effectiveness in preclinical testing 2
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
... 5500TM is the worlds first spot ... and heart rate to use reflectance ... uses SPO Medicals patented technology to ... more usable for many patients and ...
All-in-One Fingertip Oximeter...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: